Immune‐mediated neuromuscular complications of graft‐versus‐host disease

2021 ◽  
Author(s):  
Jacqui‐Lyn Saw ◽  
M. Hasib Sidiqi ◽  
Michelle L. Mauermann ◽  
Hassan Alkhateeb ◽  
Elie Naddaf
Keyword(s):  
Graft Versus Host Disease ◽  
Host Disease ◽  
Graft Versus Host ◽  
Immune Mediated ◽  
Neuromuscular Complications

scholarly journals Extracorporeal photopheresis reverses experimental graft-versus-host disease through regulatory T cells

Blood ◽  
2008 ◽  
Vol 112 (4) ◽  
pp. 1515-1521 ◽  
Author(s):  
Erin Gatza ◽  
Clare E. Rogers ◽  
Shawn G. Clouthier ◽  
Kathleen P. Lowler ◽  
Isao Tawara ◽  
...  
Keyword(s):  
T Cells ◽  
Regulatory T Cells ◽  
Graft Versus Host Disease ◽  
White Blood Cells ◽  
Extracorporeal Photopheresis ◽  
Ultraviolet A ◽  
Host Disease ◽  
Graft Versus Host ◽  
Immune Mediated ◽  
Novel Method

Abstract Extracorporeal photopheresis (ECP), a technique that exposes isolated white blood cells to photoactivatable 8-methoxypsoralen and ultraviolet A radiation, is used clinically to treat cutaneous T-cell lymphoma and immune-mediated diseases such as graft-versus-host disease (GVHD). ECP is thought to control these diseases in part through direct induction of lymphocyte apoptosis, but its effects on the immune system beyond apoptosis remain poorly characterized. We have developed a novel method for incorporating ECP treatment into well-established and clinically relevant murine models of GVHD to examine its effects during an ongoing immune response. We demonstrate that the transfer of cells treated with ECP reverses established GVHD by increasing donor regulatory T cells and indirectly reducing the number of donor effector lymphocytes that themselves had never been exposed to psoralen and ultraviolet A radiation.

Recognizing and Managing Chronic Graft-Versus-Host Disease

Hematology ◽  
2008 ◽  
Vol 2008 (1) ◽  
pp. 134-141 ◽  
Author(s):  
Stephanie J. Lee ◽  
Mary E. D. Flowers
Keyword(s):  
Graft Versus Host Disease ◽  
Hematopoietic Cell Transplantation ◽  
Chronic Gvhd ◽  
Correct Diagnosis ◽  
Organ Damage ◽  
Consensus Conference ◽  
First Year ◽  
Host Disease ◽  
Graft Versus Host ◽  
Immune Mediated

Abstract Chronic graft-versus-host disease (GVHD) is an immune-mediated disorder that occurs frequently after allogeneic hematopoietic cell transplantation (HCT). Most cases are diagnosed within the first year at a median of 4 to 6 months after HCT, but 5–10% of cases are initially diagnosed beyond the first post-transplant year. Chronic GVHD most often involves the skin and mouth, but almost any other organ system can be involved. Correct diagnosis is critical so that appropriate therapy can be started promptly to minimize symptoms and prevent irreversible organ damage. Initial treatment should be with cortico-steroid-based therapy. Optimal secondary treatment as not been established, although a large number of agents may provide benefits. A 2004 NIH conference focused on development of consensus criteria for chronic GVHD. Six papers published in 2005 and 2006 propose consensus definitions for chronic GVHD diagnosis and scoring, pathology, biomarkers, response criteria, supportive care and design of clinical trials. This review will focus on common clinical presentations and principles for managing chronic GVHD. The most frequently used secondary therapies and ongoing trials are summarized. New concepts from the NIH consensus conference are discussed.

scholarly journals Interleukin-22 Protects Intestinal Stem Cells from Immune-Mediated Tissue Damage and Regulates Sensitivity to Graft versus Host Disease

Immunity ◽  
2012 ◽  
Vol 37 (2) ◽  
pp. 339-350 ◽  
Author(s):  
Alan M. Hanash ◽  
Jarrod A. Dudakov ◽  
Guoqiang Hua ◽  
Margaret H. O’Connor ◽  
Lauren F. Young ◽  
...  
Keyword(s):  
Stem Cells ◽  
Graft Versus Host Disease ◽  
Tissue Damage ◽  
Intestinal Stem Cells ◽  
Host Disease ◽  
Graft Versus Host ◽  
Interleukin 22 ◽  
Immune Mediated

Positive Impact of Chronic Graft-Versus Host Disease on Survival in 928 Allogeneic Hematopoietic Stem Cell Transplant Recipients

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 1952-1952 ◽  
Author(s):  
Gunhan Gurman ◽  
Pinar Ataca ◽  
Erden Atilla ◽  
Sinem Civriz Bozdag ◽  
Selami Kocak Toprak ◽  
...  
Keyword(s):  
Stem Cell ◽  
Graft Versus Host Disease ◽  
Lower Risk ◽  
Acute Gvhd ◽  
Chronic Gvhd ◽  
Conditioning Regimen ◽  
Hematopoietic Stem ◽  
Host Disease ◽  
Graft Versus Host ◽  
Immune Mediated

Abstract Introduction: Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) is a standard curative treatment option in hematological diseases. The anti-leukemic activity relies not only the effects of conditioning regimen but also the immune mediated graft-versus leukemia (GVL) effect. Donor T cells are responsible for the GVL and causes complications namely acute and chronic graft versus host disease (GVHD). Herein, we aim to present the relation of graft versus host disease with survival and relapse. Patients and Methods: We retrospectively evaluated 928 Allo-HSCT between 1989 and 2015 followed in our institution. Chi-square test and student's t test were used in comparison. P <0.05 was considered statistically significant. Results: 551 patients were male (59%) and 377 patients (41%) were female. The median age of the group was 34 (range 15 -71). Patients received stem cell from related donors more frequently (85%) with HLA full match (66%). Peripheral blood was the source of stem cells in 645 recipient (70%) followed by bone marrow (28%). 75 patients were diagnosed as benign hematological disorders. The most common malign hematological diagnosis was acute myeloid leukemia in 366 patients (39%). Patients received 80% of myeloablative conditioning regimen prior to transplantation. 43% of the patients diagnosed as acute GVHD and 45% had chronic GVHD. 798 achieved engraftment (86%) neutrophil engraftment median of 16 days, platelet engraftment median of 14 days. Relapse was detected in 6% of patients. The overall survival (OS) was 59 months and progression free survival (PFS) was 33 months. Acute GVHD had no impact on OS, PFS, relapse rate. The OS in patients with chronic GVHD was significantly higher than in GVHD negative patients (68.8 vs 56.9, P=0.009). Although chronic GVHD patients had lower risk of relapse and higher PFS, the results were not statistically significant. Conclusion: GVHD is a serious complication and important cause of post transplant morbidity. Chronic GVHD is associated with lower risk of relapse in previous studies. In this study, we have concluded the improved OS in patients with chronic GVHD. The immune mediated GVL effect may be the reason for anti-leukemia effect and improved survival. Disclosures No relevant conflicts of interest to declare.

P.14Immune-mediated neuromuscular complications of graft-versus-host disease

2019 ◽  
Vol 29 ◽  
pp. S45
Author(s):  
J. Saw ◽  
M. Sidiqi ◽  
M. Mauermann ◽  
H. Alkhateeb ◽  
E. Naddaf
Keyword(s):  
Graft Versus Host Disease ◽  
Host Disease ◽  
Graft Versus Host ◽  
Neuromuscular Complications
Sign in / Sign up

Export Citation Format

Share Document